Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-30T20:23:20.819Z Has data issue: false hasContentIssue false
  • English
  • Français

An Outbreak of Burkholderia cepacia Complex Associated with Intrinsically Contaminated Nasal Spray

Published online by Cambridge University Press:  02 January 2015

Susan A. Dolan ,
Elaine Dowell ,
John J. LiPuma ,
Sondra Valdez ,
Kenny Chan  and
John F. James
Susan A. Dolan*
Affiliation:
The Children's Hospital, Denver, Colorado
Elaine Dowell
Affiliation:
The Children's Hospital, Denver, Colorado
John J. LiPuma
Affiliation:
University of Michigan, Ann Arbor, Michigan
Sondra Valdez
Affiliation:
The Children's Hospital, Denver, Colorado
Kenny Chan
Affiliation:
The Children's Hospital, Denver, Colorado
John F. James
Affiliation:
The Children's Hospital, Denver, Colorado
*
Department of Epidemiology, The Children's Hospital, 13123 East 16th Avenue, Box 276, Aurora, CO 80045 ([email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective.

To determine the source of Burkholderia cepacia complex associated with a hospital outbreak and describe the measures taken to identify and confirm the source.

Setting.

A 250-bed, tertiary care pediatric hospital in Denver, Colorado.

Methods.

An epidemiologic investigation was used to identify possible causes for an apparent outbreak of B. cepacia complex in pediatric patients who had new positive cultures with this organism from December 2003 to February 2004. Chart review, microbiology reports, surgical records, site visits, literature review, staff interviews, and cultures of common products and equipment were performed to determine a source of contamination. Random amplified polymorphic DNA and pulsed-field gel electrophoresis typing, performed by 2 independent laboratories, were used for molecular typing of patient and source isolates.

Results.

Five pediatric patients had new positive B. cepacia complex cultures from either the sinus or the respiratory tract, and all 5 patients had prior exposure to 0.05% oxymetazoline hydrochloride Major Twice-A-Day 12-hour nasal spray (Proforma, Miami, FL). Four of the 5 patients had isolates that were identical to the B. cepacia complex isolates recovered from the unopened Twice-A-Day 12-hour nasal spray.

Conclusions.

Intrinsic contamination of Major Twice-A-Day 12-hour nasal spray with B. cepacia complex resulted in nosocomial transmission to 4 patients at our facility and resulted in a voluntary product recall by the manufacturer. B. cepacia complex species are common contaminants of an increasing variety of nonsterile medical products. Enhanced culture techniques may be useful in evaluating possible product contamination, suggesting additional measures that should be considered to assure the safety of products that may be used in high-risk patients.

Type
Original Article
Information
Infection Control & Hospital Epidemiology , Volume 32 , Issue 8 , August 2011 , pp. 804 - 810
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2011

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Yabuuchi, E, Kosako, Y, Oyaizu, H, et al.Proposal of Burkholderia gen. nov. and transfer of seven species of the genus Pseudomonas homology group II to the new genus, with the type species Burkholderia cepacia (Palleroni and Holmes 1981) comb. nov. Microbiol Immunol 1992;36:1251–1275.Google Scholar
2.Burkholder, W. Sour skin, a bacterial rot of onion bulbs. Phytopathology 1950;40:115–118.Google Scholar
3.McArthur, JV, Kovacic, DA, Smith, MH. Genetic diversity in natural populations of a soil bacterium across a landscape gradient. Proc Natl Acad Sci USA 1988;85:9621–9624.Google Scholar
4.Anderson, RL, Vess, RW, Carr, JH, Bond, WW, Panlilio, AL, Favero, MS. Investigations of intrinsic Pseudomonas cepacia contamination in commercially manufactured povidone-iodine. Infect Control Hosp Epidemiol 1991;12:297–302.CrossRefGoogle ScholarPubMed
5.Doit, C, Loukil, C, Simon, AM, et al.Outbreak of Burkholderia cepacia bacteremia in a pediatric hospital due to contamination of lipid emulsion stoppers. J Clin Microbiol 2004;42:2227–2230.Google Scholar
6.El Shane, S, Al Sattar, H, Al Khal, A. Nosocomial Burkholderia cepacia pseudo-outbreak due to contaminated “Savlon” in the bronchoscopy unit. Qatar Med J 2003:12.Google Scholar
7.Frank, MJ, Schaffner, W. Contaminated aqueous benzalkonium chloride: an unnecessary hospital infection hazard. JAMA 1976;236:2418–2419.Google Scholar
8.Hamill, RJ, Houston, ED, Georghiou, PR, et al.An outbreak of Burkholderia (formerly Pseudomonas) I respiratory tract colonization and infection associated with nebulized albuterol therapy. Ann Intern Med 1995;122:762–766.Google Scholar
9.Kaitwatcharachai, C, Silpapojakul, K, Jitsurong, S, Kalnauwakul, S. An outbreak of Burkholderia cepacia bacteremia in hemodi-alysis patients: an epidemiologic and molecular study. Am J Kidney Dis 2000;36:199–204.Google Scholar
10.LiPuma, JJ. Burkholderia and emerging pathogens in cystic fibrosis. Semin Respir Crit Care Med 2003;24:681–692.Google ScholarPubMed
11.Matrician, L, Ange, G, Burns, S, et al.Outbreak of nosocomial Burkholderia cepacia infection and colonization associated with intrinsically contaminated mouthwash. Infect Control Hosp Epidemiol 2000;21:739–741.CrossRefGoogle ScholarPubMed
12.Nasser, RM, Rahi, AC, Haddad, MF, Daoud, Z, Irani-Hakime, N, Almawi, WY. Outbreak of Burkholderia cepacia bacteremia traced to contaminated hospital water used for dilution of an alcohol skin antiseptic. Infect Control Hosp Epidemiol 2004;25:231–239.Google Scholar
13.Pegues, DA, Carson, LA, Anderson, RL, et al.Outbreak of Pseudomonas cepacia bacteremia in oncology patients. Clin Infect Dis 1993;16:407–411.Google Scholar
14.Reboli, AC, Koshinski, R, Arias, K, Marks-Austin, K, Stieritz, D, Stull, TL. An outbreak of Burkholderia cepacia lower respiratory tract infection associated with contaminated albuterol nebulization solution. Infect Control Hosp Epidemiol 1996;17:741–743.Google Scholar
15.Govan, JR, Brown, PH, Maddison, J, et al.Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 1993;342:15–19.Google Scholar
16.Saiman, L. Multidrug-resistant organisms in cystic fibrosis: an increasingly important problem. APUA Newsl 1996;14:1–6.Google Scholar
17.Dey, BP, Engley, FB Jr, Methodology for recovery of chemically treated Staphylococcus aureus with neutralizing medium. Appl Environ Microbiol 1983;45:1533–1537.Google Scholar
18.Engley, F, Dey, B. A universal neutralizing medium for antimicrobial chemicals. Chem Spec Manuf Assoc Proc 1970:56.Google Scholar
19.Henry, DA, Campbell, ME, LiPuma, JJ, Speert, DP. Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium. J Clin Microbiol 1997;35:614–619.Google Scholar
20.LiPuma, JJ, Dulaney, BJ, McMenamin, JD, et al.Development of rRNA-based PCR assays for identification of Burkholderia cepacia complex isolates recovered from cystic fibrosis patients. J Clin Microbiol 1999;37:3167–3170.Google Scholar
21.LiPuma, JJ, Spilker, T, Coenye, T, Gonzalez, CF. An epidemic Burkholderia cepacia complex strain identified in soil. Lancet 2002;359:2002–2003.Google Scholar
22.Vermis, K, Coenye, T, Mahenthiralingam, E, Nelis, HJ, Vandamme, P. Evaluation of species-specific recA-based PCR tests for genomovar level identification within the Burkholderia cepacia complex. J Med Microbiol 2002;51:937–940.Google Scholar
23.Swaminathan, B, Barrett, TJ, Hunter, SB, Tauxe, RV. PulseNet: the molecular subtyping network for foodborne bacterial disease surveillance, United States. Emerg Infect Dis 2001;7:382–389.CrossRefGoogle Scholar
24.Chen, JS, Witzmann, KA, Spilker, T, Fink, RJ, LiPuma, JJ. Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis. J Pediatr 2001;139:643–649.Google Scholar
25.Mahenthiralingam, E, Campbell, ME, Henry, DA, Speert, DP. Epidemiology of Burkholderia cepacia infection in patients with cystic fibrosis: analysis by randomly amplified polymorphic DNA fingerprinting. J Clin Microbiol 1996;34:2914–2920.Google Scholar
26.Centers for Disease Control and Prevention (CDC). Manufacturer's recall of nasal spray contaminated with Burkholderia cepacia complex. MMWR Morb Mortal Wkly Rep 2004;53:246.Google Scholar
27. US Food and Drug Administration. Propharma, Inc. recalls Major Twice-a-Day 12 hour nasal spray–nasal decongestant. Major Pharmaceuticals Press Release. March 28, 2004. http://www.fda.gov/Safety/Recalls/ArchiveRecalls/2004/ucm111576.htm. Accessed December 30, 2009.Google Scholar
28.US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Nasal spray and inhalation solution, suspension, and spray drug products: chemistry, manufacturing, and controls documentation. Washington, DC: US Department of Health and Human Services; 2002:1–47.Google Scholar
29.Panlilio, AL, Beck-Sague, CM, Siegel, JD, et al.Infections and pseudoinfections due to povidone-iodine solution contaminated with Pseudomonas cepacia. Clin Infect Dis 1992;14:1078–1083.Google Scholar
30.Berkelman, RL, Lewin, S, Allen, JR, et al.Pseudobacteremia attributed to contamination of povidone-iodine with Pseudomonas cepacia. Ann Intern Med 1981;95:32–36.Google Scholar
31.Craven, DE, Moody, B, Connolly, MG, et al.Pseudobacteremia caused by povidone-iodine solution contaminated with Pseudomonas cepacia. N Engl J Med 1981;305:621–623.Google Scholar
32.Weems, JJ Jr, Nosocomial outbreak of Pseudomonas cepacia associated with contamination of reusable electronic ventilator temperature probes. Infect Control Hosp Epidemiol 1993;14:583–586.Google Scholar
33.Rutala, WA, Weber, DJ, Thomann, CA, John, JF, Saviteer, SM, Sarubbi, FA. An outbreak of Pseudomonas cepacia bacteremia associated with a contaminated intra-aortic balloon pump. J Thorac Cardiovasc Surg 1988;96:157–161.Google Scholar
34.Estivariz, CF, Bhatti, LI, Pati, R, et al.An outbreak of Burkholderia cepacia associated with contamination of albuterol and nasal spray. Chest 2006;130:1346–1353.Google Scholar
35.Hutchinson, J, Runge, W, Mulvey, M, et al.Burkholderia cepacia infections associated with intrinsically contaminated ultrasound gel: the role of microbial degradation of parabens. Infect Control Hosp Epidemiol 2004;25:291–296.Google Scholar
36.Keizur, JJ, Lavin, B, Leidich, RB. Iatrogenic urinary tract infection with Pseudominas cepacia after transrectal ultrasound guided needle biopsy of the prostate. J Urol 1993;149:523–526.Google Scholar
37.Metcalf, P, Newman, K, Siegel, JD, et al.Notice to readers: nosocomial Burkholderia cepacia infections associated with exposure to sublingual probes—Texas, 2004. MMWR Morb Mortal Wkly Rep 53;796.Google Scholar
38.US Food and Drug Administration. FDA enforcement report index. http://www.fda.gov/safety/recalls/enforcementreports/default.htm. Accessed December 30, 2009.Google Scholar
39.Dixon, RE, Kaslow, RA, Mackel, DC, Fulkerson, CC, Mallison, GF. Aqueous quaternary ammonium antiseptics and disinfectants: use and misuse. JAMA 1976;236:2415–2417.Google Scholar
40.Geftic, SG, Heymann, H, Adair, FW. Fourteen-year survival of Pseudomonas cepacia in a salts solution preserved with benzalkonium chloride. Appl Environ Microbiol 1979;37:505–510.Google Scholar
41.Rutala, WA, Cole, EC. Antiseptics and disinfectants—safe and effective? Infect Control 1984;5:215–218.Google Scholar
42.O'Neil, MJ. The Merck index: an encyclopedia of chemicals, drugs, and biologicals. 10th ed. Rahway, NJ: Merck, 1983.Google Scholar
43.Winkelstein, JA, Marino, MC, Johnston, RB Jr, et al.Chronic granulomatous disease: report on a national registry of 368 patients. Medicine (Baltimore) 2000;79:155–169.Google Scholar
44.Shehabi, AA, Abu-Al-Soud, WA, Mahafzah, A, et al.Investigation of Burkholderia cepacia nosocomial outbreak with high fatality in patients suffering from diseases other than cystic fibrosis. Scand J Infect Dis 2004;36:174.Google Scholar
45.Coenye, T, LiPuma, JJ. Molecular epidemiology of Burkholderia species. Front Biosci 2003;8:e55–e67.Google Scholar
46.Reik, R, Spilker, T, LiPuma, JJ. Distribution of Burkholderia cepacia complex species among isolates recovered from persons with or without cystic fibrosis. J Clin Microbiol 2005;43:2926–2928.Google Scholar
47.Holmes, A, Nolan, R, Taylor, R, et al.An epidemic of Burkholderia cepacia transmitted between patients with and without cystic fibrosis. J Infect Dis 1999;179:1197–1205.Google Scholar
48.US Food and Drug Administration. Vicks Sinex Nasal Spray—recall. November 19, 2009. http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm191413.htm Accessed November 24, 2009.Google Scholar